All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis

IF 9.6 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Molecular Psychiatry Pub Date : 2024-08-22 DOI:10.1038/s41380-024-02694-3
Claudia Aymerich, Gonzalo Salazar de Pablo, Malein Pacho, Violeta Pérez-Rodríguez, Amaia Bilbao, Lucía Andrés, Borja Pedruzo, Idoia Castillo-Sintes, Nerea Aranguren, Paolo Fusar-Poli, Iñaki Zorrilla, Ana González-Pinto, Miguel Ángel González-Torres, Ana Catalán
{"title":"All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis","authors":"Claudia Aymerich, Gonzalo Salazar de Pablo, Malein Pacho, Violeta Pérez-Rodríguez, Amaia Bilbao, Lucía Andrés, Borja Pedruzo, Idoia Castillo-Sintes, Nerea Aranguren, Paolo Fusar-Poli, Iñaki Zorrilla, Ana González-Pinto, Miguel Ángel González-Torres, Ana Catalán","doi":"10.1038/s41380-024-02694-3","DOIUrl":null,"url":null,"abstract":"<p>Patients with schizophrenia receiving antipsychotic treatment present lower mortality rates than those who do not. However, the non-adherence rate is high, which can be partially addressed using long-acting injectable (LAI) antipsychotics. The impact of LAI treatments on all-cause mortality compared to oral antipsychotics remains unclear. To fill that gap, a random effects meta-analysis was conducted to analyze the odds ratio (OR) of all-cause, suicidal, and non-suicidal mortality among patients taking LAI antipsychotics compared to oral antipsychotics (PROSPERO:CRD42023391352). Individual and pooled LAI antipsychotics were analyzed against pooled oral antipsychotics. Sensitivity analyses were performed for study design, setting, and industry sponsorship. Meta-regressions were conducted for gender, age, antipsychotic dose, and race. Seventeen articles, total sample 12,042 patients (N = 5795 oral, N = 6247 LAI) were included. Lower risk of all-cause mortality for patients receiving LAI antipsychotics vs receiving oral antipsychotics was found (OR = 0.79; 95%CI = 0.66–0.95). Statistical significance was maintained when only studies comparing the same LAI and oral antipsychotic were included (OR = 0.79; 95%CI = 0.66–0.95; p = &lt;0.01), as well as for non-suicidal mortality (OR = 0.77: 95%CI = 0.63–0.94; p = 0.01), but not for suicidal mortality (OR = 0.86; 95%CI = 0.59–1.26; p = 0.44). Mortality reduction was more pronounced for LAI antipsychotics in first-episode psychosis (FEP) (OR = 0.79; 95%CI = 0.66–0.96) compared to chronic psychosis. No individual LAI reported statistically significant differences against all pooled oral antipsychotics. LAI antipsychotics are associated with a lower risk of all-cause and non-suicidal mortality in individuals with schizophrenia compared to oral antipsychotics. Better adherence to the medication and health services may explain this difference. Whenever possible, the use of LAIs should be considered from the FEP.</p>","PeriodicalId":19008,"journal":{"name":"Molecular Psychiatry","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41380-024-02694-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with schizophrenia receiving antipsychotic treatment present lower mortality rates than those who do not. However, the non-adherence rate is high, which can be partially addressed using long-acting injectable (LAI) antipsychotics. The impact of LAI treatments on all-cause mortality compared to oral antipsychotics remains unclear. To fill that gap, a random effects meta-analysis was conducted to analyze the odds ratio (OR) of all-cause, suicidal, and non-suicidal mortality among patients taking LAI antipsychotics compared to oral antipsychotics (PROSPERO:CRD42023391352). Individual and pooled LAI antipsychotics were analyzed against pooled oral antipsychotics. Sensitivity analyses were performed for study design, setting, and industry sponsorship. Meta-regressions were conducted for gender, age, antipsychotic dose, and race. Seventeen articles, total sample 12,042 patients (N = 5795 oral, N = 6247 LAI) were included. Lower risk of all-cause mortality for patients receiving LAI antipsychotics vs receiving oral antipsychotics was found (OR = 0.79; 95%CI = 0.66–0.95). Statistical significance was maintained when only studies comparing the same LAI and oral antipsychotic were included (OR = 0.79; 95%CI = 0.66–0.95; p = <0.01), as well as for non-suicidal mortality (OR = 0.77: 95%CI = 0.63–0.94; p = 0.01), but not for suicidal mortality (OR = 0.86; 95%CI = 0.59–1.26; p = 0.44). Mortality reduction was more pronounced for LAI antipsychotics in first-episode psychosis (FEP) (OR = 0.79; 95%CI = 0.66–0.96) compared to chronic psychosis. No individual LAI reported statistically significant differences against all pooled oral antipsychotics. LAI antipsychotics are associated with a lower risk of all-cause and non-suicidal mortality in individuals with schizophrenia compared to oral antipsychotics. Better adherence to the medication and health services may explain this difference. Whenever possible, the use of LAIs should be considered from the FEP.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
精神分裂症患者使用长效注射与口服抗精神病药物的全因死亡风险:系统综述和荟萃分析
接受抗精神病治疗的精神分裂症患者的死亡率低于未接受治疗的患者。然而,不坚持治疗的比例很高,而长效注射(LAI)抗精神病药物可以部分解决这一问题。与口服抗精神病药物相比,长效注射抗精神病药物治疗对全因死亡率的影响仍不清楚。为了填补这一空白,我们进行了一项随机效应荟萃分析,分析了与口服抗精神病药物相比,服用LAI抗精神病药物的患者全因死亡率、自杀死亡率和非自杀死亡率的几率比(OR)(PROSPERO:CRD42023391352)。对单个和汇总的LAI抗精神病药与汇总的口服抗精神病药进行了分析。对研究设计、环境和行业赞助进行了敏感性分析。对性别、年龄、抗精神病药物剂量和种族进行了元回归。共纳入了 17 篇文章,总样本为 12042 名患者(N = 5795 名口服患者,N = 6247 名 LAI 患者)。结果发现,接受 LAI 抗精神病药物治疗的患者与接受口服抗精神病药物治疗的患者相比,全因死亡风险较低(OR = 0.79; 95%CI = 0.66-0.95)。如果只纳入比较同一种LAI和口服抗精神病药的研究,则统计意义仍然存在(OR = 0.79;95%CI = 0.66-0.95;p = 0.01),非自杀死亡率也是如此(OR = 0.77:95%CI = 0.63-0.94;p = 0.01),但自杀死亡率却没有统计学意义(OR = 0.86;95%CI = 0.59-1.26;p = 0.44)。与慢性精神病相比,LAI抗精神病药物对首发精神病(FEP)患者死亡率的降低更为显著(OR = 0.79; 95%CI = 0.66-0.96)。与所有口服抗精神病药物相比,没有一种LAI药物的差异具有统计学意义。与口服抗精神病药物相比,LAI抗精神病药物与精神分裂症患者较低的全因和非自杀死亡风险相关。对药物和医疗服务更好的依从性可能是造成这种差异的原因。在可能的情况下,应从家庭治疗方案中考虑使用 LAIs。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Psychiatry
Molecular Psychiatry 医学-精神病学
CiteScore
20.50
自引率
4.50%
发文量
459
审稿时长
4-8 weeks
期刊介绍: Molecular Psychiatry focuses on publishing research that aims to uncover the biological mechanisms behind psychiatric disorders and their treatment. The journal emphasizes studies that bridge pre-clinical and clinical research, covering cellular, molecular, integrative, clinical, imaging, and psychopharmacology levels.
期刊最新文献
Genetic and functional analyses of CTBP2 in anorexia nervosa and body weight regulation Peripartum allopregnanolone blood concentrations and depressive symptoms: a systematic review and individual participant data meta-analysis Cortico-limbic volume abnormalities in late life depression are distinct from β amyloid and white matter pathologies Neuroimaging-based variability in subtyping biomarkers for psychiatric heterogeneity White matter microstructure in obesity and bipolar disorders: an ENIGMA bipolar disorder working group study in 2186 individuals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1